Xeris Biopharma (NASDAQ:XERS) Sees Unusually-High Trading Volume - Should You Buy?

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Get Free Report) saw unusually-strong trading volume on Friday . Approximately 4,159,031 shares changed hands during mid-day trading, an increase of 93% from the previous session's volume of 2,159,568 shares.The stock last traded at $4.88 and had previously closed at $4.56.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on XERS shares. Piper Sandler reiterated a "neutral" rating and issued a $4.00 price objective (up from $3.00) on shares of Xeris Biopharma in a report on Friday, March 7th. Jefferies Financial Group restated a "buy" rating and set a $6.00 target price (up from $4.00) on shares of Xeris Biopharma in a report on Wednesday, January 29th. Craig Hallum increased their target price on Xeris Biopharma from $5.00 to $6.50 and gave the company a "buy" rating in a report on Friday, March 7th. HC Wainwright restated a "buy" rating and set a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a report on Friday, March 7th. Finally, Leerink Partners increased their target price on Xeris Biopharma from $5.00 to $6.00 and gave the company an "outperform" rating in a report on Friday, March 7th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $5.92.

Xeris Biopharma Trading Up 3.7 %

The firm has a fifty day simple moving average of $3.71 and a two-hundred day simple moving average of $3.34. The firm has a market cap of $802.80 million, a PE ratio of -11.59 and a beta of 2.32.

Remove Ads

Institutional Investors Weigh In On Xeris Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. China Universal Asset Management Co. Ltd. raised its position in shares of Xeris Biopharma by 10.3% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 31,611 shares of the company's stock worth $107,000 after acquiring an additional 2,954 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Xeris Biopharma by 4.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company's stock worth $273,000 after acquiring an additional 3,447 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Xeris Biopharma by 31.0% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company's stock worth $55,000 after acquiring an additional 3,847 shares in the last quarter. GPS Wealth Strategies Group LLC raised its position in shares of Xeris Biopharma by 6.2% in the 4th quarter. GPS Wealth Strategies Group LLC now owns 66,925 shares of the company's stock worth $227,000 after acquiring an additional 3,900 shares in the last quarter. Finally, Janney Montgomery Scott LLC raised its position in shares of Xeris Biopharma by 31.4% in the 4th quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock worth $78,000 after acquiring an additional 5,500 shares in the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.